Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
HUMA
HUMA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
HUMA News
Humacyte Secures Congressional Funding for Bioengineered Vessels
6d ago
seekingalpha
Humacyte Secures DOD Funding for Bioengineered Blood Vessels
6d ago
stocktwits
BTIG Affirms Buy Rating on Humacyte, Keeps $6 Price Target Intact
Nov 21 2025
Benzinga
D. Boral Capital Reiterates Buy Rating on Humacyte with $25 Price Target Intact
Nov 20 2025
Benzinga
Benchmark Reaffirms Buy Rating on Humacyte, Adjusts Price Target to $11
Nov 13 2025
Benzinga
D. Boral Capital Reiterates Buy Rating on Humacyte with $25 Price Target Intact
Nov 12 2025
Benzinga
Robust Earnings and Biotech Strength Drive Midweek Momentum
Nov 12 2025
Newsfilter
Humacyte Reveals 12-Month Cash Reserves and Boosts Symvess Adoption After Securing $56.5M in Funding
Nov 12 2025
SeekingAlpha
Humacyte, Inc. Reports Reduced Losses in Q3
Nov 12 2025
NASDAQ.COM
Humacyte Reports GAAP EPS of -$0.11, Exceeding Estimates by $0.05; Revenue of $0.75M Falls Short by $0.17M
Nov 12 2025
SeekingAlpha
Humacyte Q3 2025 Earnings Forecast
Nov 11 2025
SeekingAlpha
Humacyte, Inc. (HUMA) Outperforms Market Returns: Key Insights to Consider
Oct 24 2025
NASDAQ.COM
Humacyte Reveals Pricing for $60 Million Oversubscribed Registered Direct Offering
Oct 07 2025
Newsfilter
Humacyte Stock Plummets Following Announcement of $60M Direct Offering Pricing
Oct 07 2025
SeekingAlpha
D. Boral Capital Continues to Recommend Buying Humacyte (HUMA)
Oct 07 2025
NASDAQ.COM
D. Boral Capital Reiterates Buy Rating on Humacyte with $25 Price Target Intact
Oct 06 2025
Benzinga
Show More News
